A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, de Sá JC, Edland A, Frederiksen JL, Heinzlef O, Karageorgiou KE, Lander Delgado RH, Landtblom AM, Macías Islas MA, Tubridy N, Gilgun-Sherki Y.